|Articles|February 13, 2013

K&L Consulting Services, Inc. of Fort Washington, PA Selects OpenClinica Enterprise Clinical Trial Software

OpenClinica announces that K&L Consulting Services, Inc. (“K&L”) of Fort Washington, Pennsylvania, has selected the OpenClinica Enterprise Edition for Electronic Data Capture (“EDC”) and clinical data management for Phase I-IV clinical trials. K&L is a Contract Research Organization (“CRO”) for clinical trial Sponsors, providing end-to-end services for all types of clinical studies, as well as post-marketing pharmacovigilance support and outcomes research.

K&L is increasing the breadth of its capabilities in the US as well as in Asia and the Pacific region, especially in China. “We welcome this opportunity to work closely with K&L to help them grow their global practice,” said Ben Baumann, Chief Operating Officer at OpenClinica, LLC.

When asked what attracted K&L to OpenClinica Enterprise, Vice President of Biostatistics and Data Management, Dr. Henry Wu said “OpenClinica Enterprise allows us to deploy studies quickly and cost effectively, and pass this value on to our clients.” OpenClinica’s innovative commercial open source model stands out in the realm of clinical research software. The company’s strategy is to leverage its rapidly growing global community of users and developers (currently comprising nearly 17,000 people) in order to produce high quality software in a more agile and transparent way for use across the spectrum of clinical research.

The OpenClinica software is available in two editions: The OpenClinica Community Edition is freely available under a common open source license. The OpenClinica Enterprise Edition pairs the open source technology with a regulatory compliance infrastructure and robust support services. According to Baumann, “OpenClinica’s model allows us to focus on what makes EDC software successful--how it is implemented and supported.”

About K&L Consulting Services, LLC

K&L Consulting Services, Inc. is a Contract Research Organization (“CRO”) offering Data Management, Biostatistics, Statistical Programming and Medical Writing as well as CDISC compliant eSubmission services to the pharmaceutical, biotechnology and medical device industries worldwide. K&L’s services encompass end-to-end solutions utilizing industry data standards and rigorous operating procedures that enhance Clients’ ability to get their products approved faster at minimum risk and lower cost in order to meet patients’ needs for advanced medicines. More information at http://www.klserv.com.

About OpenClinica, LLC

Waltham, Massachusetts-based OpenClinica, LLC enhances the productivity of clinical trials through commercial open source software. With over 1,000 implementations at biopharmaceutical companies, contract research organizations, academic, and government organizations worldwide, the OpenClinica software facilitates electronic data capture and data management, increasing the speed of collection and quality of data in clinical trials. OpenClinica supports HIPAA, 21 CFR Part 11, and other regulatory guidelines and is designed as a standards-based, extensible, and modular platform. For more information – including product and source code downloads – visit http://www.openclinica.com or follow @OpenClinica on Twitter.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related to this article

November 6th, 2026

What FDA Inspections Reveal About the Quality of APAC Clinical Trial Sites

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how FDA inspection findings at APAC sites compare with those in the US and Europe, and why the common issues, such as informed consent versioning, are not unique to the region.

November 6th, 2026

ACT Brief: Asia Pacific Site Perceptions, Community Access Gap, and VeonGen Gene Therapy Alignment

In today’s ACT Brief, we examine why outdated views of Asia Pacific trial sites persist, how community access gaps reflect both patient costs and site infrastructure, and how VeonGen has aligned with the FDA on a pivotal gene therapy trial design.

Ten key risk indicators can flag recurring good clinical practice problems in noncompliance, safety, data quality, and oversight, but only when normalization, trial timing, and combined signals are taken into account. Credit: Stock.Adobe.com/Andrey Popov.

November 6th, 2026

The 10 Most Powerful Study KRIs in RBQM and GCP Issues They Can Prevent

Risk-based quality management depends on knowing what to monitor and on interpreting what the signals mean.

November 5th, 2026

Why Outdated Perceptions of APAC Clinical Trial Sites Persist Among Smaller Biotechs

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how regulatory reform and inspection data contradict the view that APAC sites are slower or lower quality, and why sponsors need to update their assumptions.

November 5th, 2026

Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health

In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.

November 5th, 2026

ACT Brief: Capturing Trial Friction, AI Matching Model Comparisons, and Boehringer’s Oncology Deal

In today’s ACT Brief, we examine how capturing friction in real time can reveal site burden, how OpenAI and Mistral compare on clinical trial matching, and how Boehringer Ingelheim is licensing early-stage oncology programs from SBP Group.

November 4th, 2026

Comparing OpenAI and Mistral on Clinical Trial Matching

Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.

November 4th, 2026

The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time

In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.